When push comes to shove, President Cyril Ramaphosa’s talk of building a more capable state hasn’t always been backed up by the appointment of committed and capable people to key government positions. His decision regarding a new Director-General for health will say a lot about how serious he actually is about addressing the country’s many health challenges, argues Spotlight editor Marcus Low.
In South Africa, as in many places, pharmaceutical companies are not free to change medicine prices as they wish. In his latest Inside The Box column, Dr Andy Gray unpacks how medicines prices are regulated in the country and considers how this regulatory framework might change.
There has been much confusion and misunderstandings about how cannabis and associated products are regulated in South Africa, with government’s own missteps adding to the uncertainty. In his last Inside The Box column for the year, Dr Andy Gray clearly sets out the current legal and regulatory situation and where we’re heading.
In several countries, the public is given an opportunity to share their views with regulators before new medicines are registered or to engage with those choosing essential medicines. In South Africa, however, opportunities for such public participation remains limited. In his latest Inside The Box column, Dr Andy Gray takes a look at how public participation is handled elsewhere and how it could be improved here.
Rather than trying to do everything from scratch, medicines regulators from different countries are increasingly sharing the load between them by ‘relying’ on each other’s work. In his latest Inside The Box column, Dr Andy Gray explains how such ‘reliance mechanisms’ can help regulators make decisions more quickly and efficiently, and digs into the details of how South Africa can make the most of these mechanisms.
For over 20 years, the law has required that the Minister of Health issues regulations to govern the advertising of medicines in South Africa, but as yet no such regulations are in place. In his latest Inside The Box column, Dr Andy Gray considers what this means for the marketing of medicines in the country.
It is easy to claim one is “following the scientific evidence”, but what does it mean to actually do so? In his latest Inside The Box column, Dr Andy Gray considers how evidence-based health policy and guidelines can and should be made.
Clinical trial participants appear to be well protected in South Africa, particularly as the country’s guidelines recognise the risks of research with international collaborators. The sudden end of US-funded clinical trials, however, is exposing some limitations of ethics codes and guidelines, argues Dr Andy Gray.
What medicines do you need prescriptions for and who is authorised to write those prescriptions is not a straight-forward matter. In his latest Inside The Box column, Dr Andy Gray explains how the system works now and sets out how it might be improved.
In the first of a new series of monthly columns for Spotlight, Dr Andy Gray considers what we mean when we refer to medicines as ‘essential’ – something that is routinely done by the WHO and the health authorities in many countries.
Professor Lucy Gilson scooped the prestigious international Virchow Prize. She chats to Biénne Huisman about her upbringing, unexpected dive into the world of public health, and shares her thoughts on National Health Insurance. She says it will take more than money to fix our health system.
An innovative health programme is thriving and making a difference in the lives of people in a rural Eastern Cape community. Sue Segar spent time with the project, walking with “nomakhayas” from house-to-house and taking a ferry trip across the Xhora river.
